Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuridase is a dietary supplement and nutraceutical product primarily formulated with N-acetylneuraminic acid (sialic acid), typically in combination with B-complex vitamins such as pyridoxine (Vitamin B6) and cyanocobalamin (Vitamin B12). It is developed and marketed by Alfasigma for the support of cognitive function and neurological health. The primary active component, N-acetylneuraminic acid, is a vital structural element of gangliosides and glycoproteins found in high concentrations within the cerebral cortex and synaptic membranes. Neuridase acts by providing the necessary building blocks for the synthesis and maintenance of neural membranes, thereby facilitating effective synaptic transmission and neuroprotection. It is commonly indicated for patients experiencing cognitive fatigue, age-associated memory impairment, or recovering from neurological stressors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neuridase.